IntegriChain Leaders to Speak at Informa's Fall 2026 MDRP, GTN, and Trade & Channel Summits
Company experts will deliver sessions on government pricing policy, 340B, gross-to-net strategy, and trade and distribution trends across three premier industry events this fall
PHILADELPHIA, Sept. 22, 2026 /PRNewswire/ -- IntegriChain, the leading provider of pharma net revenue optimization technology, data, and consulting for the life sciences industry, today announced that its subject matter experts will present at three of Informa Connect's flagship fall conferences: the Medicaid Drug Rebate Program (MDRP) Summit, the Pharma/Biotech Gross-to-Net (GTN) Summit, and Trade & Channel Strategies. Across the three events, IntegriChain leaders will share insights on government pricing and contracting, 340B, gross-to-net forecasting, and the future of pharmaceutical distribution and access.
"Government pricing, 340B, gross-to-net, and trade and channel strategy are more interconnected and more consequential than ever for our clients," said Jeff Baab, Partner, Advisory Services with IntegriChain "These conferences give our team the opportunity to bring real-world perspective from the hundreds of manufacturers we support directly to the industry."
Baab, Willis Speaks on Evolving Contracting Environment
At the Medicaid Drug Rebate Program (MDRP) Summit 2026, taking place October 5–7, 2026, at the Fairmont Chicago Millennium Park in Chicago, IL, Jeff Baab, Partner, Advisory Services at IntegriChain, will present "Updates on Landscape of Government Pricing and Contracting" on Wednesday, October 7, at 9:40 AM. Baab will share his perspective on the evolving government pricing and contracting environment, drawing on his extensive experience advising manufacturers on gross-to-net, contracting, and market access across both commercial and government channels.
340B industry expert Clay Willis, Partner, Advisory Services at IntegriChain will also present "340B Movement to Have All 340B Claims in One System of Record" on Wednesday, October 7 at 10:50 AM, while also offering an update on the recent 340B events such as the the rebate model pilot program #2, contract and in-house pharmacy policies, patient definition, plus other activities occurring in the market.
At the Pharma/Biotech Gross-to-Net (GTN) Summit 2026, taking place November 16–18, 2026, at the Hilton at Penn's Landing in Philadelphia, PA, two IntegriChain leaders will take the stage to share perspectives on the issues shaping gross-to-net strategy.
On Monday, November 16, at 4:30 PM, Jennifer Sharpe, Vice President, Gross-to-Net Consulting and Facilitator of the Revenue Analytics Collaborative at IntegriChain, will host and moderate "Hot Topic Roundtable Discussions: Sponsored by IntegriChain's Revenue Analytics Collaborative (RAC)" for RAC members. The session will bring together participants from the 800+ member industry peer network Sharpe co-founded to discuss the topics shaping GTN strategy today.
On Tuesday, November 17, at 10:55 AM, Walt Worsham, Managing Director at IntegriChain, will present "Drug Pricing Policy & Regulatory Landscape Updates," offering an update on the drug pricing policy and regulatory developments most relevant to gross-to-net forecasting, accruals, and contracting strategy.
At Trade & Channel Strategies 2026, taking place December 8–10, 2026, at the W Hotel in Philadelphia, PA, Bill Roth, Senior Vice President and Managing Partner, Consulting and Advisory at IntegriChain, will deliver a keynote address on the state of the channel. His remarks will examine the disruption facing today's pharmacy and distribution landscape, from reimbursement pressure at national retail chains to the downstream effects on specialty and general medicine brands.
For more insights on government pricing, 340B, and gross-to-net strategy from IntegriChain's team, visit www.integrichain.com or follow IntegriChain on LinkedIn.
About IntegriChain
IntegriChain delivers biopharma's only comprehensive data-driven commercialization platform from strategy to operational execution connecting the commercial, financial, and operational dimensions of drug access and profitability. Our ICyte® platform integrates technology, data, consulting, and managed services to unify critical workflows replacing manual processes with integrated analytics and precision controls.
Biopharma relies on IntegriChain to optimize patient access and net revenue performance, reduce leakage, and strengthen compliance, ensuring every life-changing therapy reaches patients with speed, affordability, and sustainability. Backed by Nordic Capital, a leading sector-specialized private equity investor with a broad portfolio in healthcare and technology. IntegriChain is headquartered in Philadelphia, PA, with a location in Pune, India. For more information, visit www.integrichain.com or follow us on LinkedIn.
For more information, visit www.integrichain.com.
Media Contact
Brandy Jensen, Senior Director Marketing, IntegriChain
SOURCE IntegriChain, Inc.
Share this article